# US 12,758,618 B2 · Compositions for treating respiratory tract infection and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,758,618 B2
- Document ID: US12758618B2
- Status: Granted
- Kind: B2
- Application number: 17/911,972
- Filed: 2021-03-16
- Published: 2023-08-17
- Granted: 2026-10-13
- Earliest claimed: 2020-03-16
- Assignees: Lateral IP Pty Ltd
- Applicants: Lateral IP Pty Ltd
- Inventors: Andrew Gearing; David Kenley
- Web page: https://patentgrep.com/patent/US12758618B2

## CPC

- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating a respiratory tract infection in a subject by administering to the subject in need thereof a therapeutically effective amount of C-terminal fragments of growth hormone, including LAT8881, otherwise known as AOD9604, or LAT9991F, and pharmaceutically acceptable salts thereof, are described.

## Claims

### Claim 1

A method of treating a respiratory tract infection in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a peptide of formula (I), or a pharmaceutically acceptable salt thereof:
(I)
(SEQ ID NO: 1)
R1-CRSVEGSCG-R2
wherein
R1 is selected from the group consisting of YLRIVQ (SEQ ID NO:45), LRIVQ (SEQ ID NO: 46), RIVQ (SEQ ID NO:47), IVQ, VQ, and Q, or R1 is absent; and
R2 is F (phenylalanine) or R2 is absent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide is selected from the group consisting of YLRIVQCRSVEGSCGF (SEQ ID NO:2), LRIVQCRSVEGSCGF (SEQ ID NO: 3), CRSVEGSCG (SEQ ID NO:4) and CRSVEGSCGF (SEQ ID NO:5).

### Claim 3 (depends on 2)

The method of claim 2, wherein the peptide is YLRIVQCRSVEGSCGF (SEQ ID NO: 2).

### Claim 4 (depends on 2)

The method of claim 2, wherein the peptide is CRSVEGSCG (SEQ ID NO: 4).

### Claim 5 (depends on 2)

The method of claim 2, wherein the peptide is CRSVEGSCGF (SEQ ID NO: 5).

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein the respiratory tract infection is a virus infection.

### Claim 8 (depends on 7)

The method of claim 7, wherein the virus is selected from the group consisting of a picornavirus, a coronavirus, an influenza virus, a parainfluenza virus, a respiratory syncytial virus, an adenovirus, an enterovirus, or a metapneumovirus.

### Claim 9 (depends on 8)

The method of claim 8, wherein the virus is an influenza virus or a coronavirus.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method comprises administering the peptide to the subject orally.